Our mission
Set a new standard of care for people living with inflammatory and degenerative disorders
Inflammatory and tissue degenerative disorders impact many lives
More than a billion people suffer from chronic diseases where inflammation and tissue degeneration significantly limit daily activities and reduce quality of life. For example, loss of joint mobility due to arthritis causes disability, affecting walking and climbing stairs, whilst eye conditions can affect reading, driving and recognising faces. This places an enormous burden on the healthcare system and has a huge socioeconomic impact by reducing the productivity of sufferers and their carers.
Link_TSG6
Link_TSG6 is a protein biologic based on TSG-6, a protective protein that is made in all of our organs and tissues in response to inflammation and trauma. Link_TSG6 has a unique and potent combination of anti-inflammatory and tissue-protecting properties making it a ‘platform-technology’ applicable to a broad range of diseases.
Link Biologics is a University of Manchester spinout company launched in 2021. Link_TSG6, our core asset, has been developed with support from world-renowned partners and funders. Our expertise in musculoskeletal and ophthalmological diseases has prioritised initial development in two programmes: Dry Eye Disease (DED) and Osteoarthritis (OA).